| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ACCD Stock Overview
Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.
Accolade Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.21 |
| 52 Week High | US$59.93 |
| 52 Week Low | US$18.72 |
| Beta | 0 |
| 1 Month Change | -18.01% |
| 3 Month Change | -47.98% |
| 1 Year Change | -61.39% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.95% |
Recent News & Updates
Accolade Impresses With Revenue Growth But Faces Operating Losses
Accolade went public in July 2020, raising $220 million in a U.S. IPO. The firm provides a healthcare information platform for enterprises and end users. ACCD has grown topline revenue sharply but is producing high and increasing operating losses, so my outlook is Neutral on the stock.
Accolade: I May Add To My Position
Accolade has seen continued growth this year. Solid organic growth has been accelerated by two bolt-on deals announced this year. I like the accelerated growth trajectory as the bottom line performance has been lagging a bit, but nonetheless I see appeal increasing again.
Shareholder Returns
| ACCD | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -3.4% | 1.5% | -0.5% |
| 1Y | -61.4% | 16.4% | 13.7% |
Return vs Industry: ACCD underperformed the US Healthcare industry which returned 16.4% over the past year.
Return vs Market: ACCD underperformed the US Market which returned 13.7% over the past year.
Price Volatility
| ACCD volatility | |
|---|---|
| ACCD Average Weekly Movement | 12.6% |
| Healthcare Industry Average Movement | 8.0% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: ACCD is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: ACCD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,350 | Raj Singh | https://www.accolade.com |
Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services.
Accolade Fundamentals Summary
| ACCD fundamental statistics | |
|---|---|
| Market Cap | US$1.35b |
| Earnings (TTM) | -US$93.29m |
| Revenue (TTM) | US$275.50m |
4.9x
P/S Ratio-14.5x
P/E RatioIs ACCD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACCD income statement (TTM) | |
|---|---|
| Revenue | US$275.50m |
| Cost of Revenue | US$153.05m |
| Gross Profit | US$122.45m |
| Expenses | US$215.74m |
| Earnings | -US$93.29m |
Last Reported Earnings
Nov 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | 44.45% |
| Net Profit Margin | -33.86% |
| Debt/Equity Ratio | 35.5% |
How did ACCD perform over the long term?
See historical performance and comparisonValuation
Is Accolade undervalued compared to its fair value and its price relative to the market?
1.72x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ACCD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ACCD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ACCD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: ACCD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACCD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACCD is good value based on its PB Ratio (1.7x) compared to the US Healthcare industry average (2.7x).
Future Growth
How is Accolade forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
-22.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACCD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACCD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACCD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACCD's revenue (24.6% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ACCD's revenue (24.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACCD is forecast to be unprofitable in 3 years.
Past Performance
How has Accolade performed over the past 5 years?
-17.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACCD is currently unprofitable.
Growing Profit Margin: ACCD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACCD is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare ACCD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACCD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.5%).
Return on Equity
High ROE: ACCD has a negative Return on Equity (-11.83%), as it is currently unprofitable.
Financial Health
How is Accolade's financial position?
Financial Position Analysis
Short Term Liabilities: ACCD's short term assets ($407.6M) exceed its short term liabilities ($184.6M).
Long Term Liabilities: ACCD's short term assets ($407.6M) exceed its long term liabilities ($290.1M).
Debt to Equity History and Analysis
Debt Level: ACCD has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ACCD's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACCD has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ACCD has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 10.3% each year
Dividend
What is Accolade current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACCD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACCD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACCD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACCD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACCD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Raj Singh (53 yo)
6.25yrs
Tenure
US$2,592,000
Compensation
Mr. Rajeev Singh, also known as Raj, serves as Director at Amperity, Inc. He has been the Chief Executive Officer and Executive Director of Accolade, Inc. since October 2015 and also serves as its Chairman...
CEO Compensation Analysis
Compensation vs Market: Raj's total compensation ($USD2.59M) is about average for companies of similar size in the US market ($USD3.62M).
Compensation vs Earnings: Raj's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: ACCD's management team is considered experienced (3 years average tenure).
Board Members
Experienced Board: ACCD's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.
Top Shareholders
Company Information
Accolade, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Accolade, Inc.
- Ticker: ACCD
- Exchange: NasdaqGS
- Founded: 2007
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$1.353b
- Shares outstanding: 66.96m
- Website: https://www.accolade.com
Number of Employees
Location
- Accolade, Inc.
- 660 West Germantown Pike
- Suite 500
- Plymouth Meeting
- Pennsylvania
- 19462
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/16 23:01 |
| End of Day Share Price | 2022/01/14 00:00 |
| Earnings | 2021/11/30 |
| Annual Earnings | 2021/02/28 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.